Sarepta Therapeutics’ (SRPT) “Strong-Buy” Rating Reiterated at WBB Securities
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “strong-buy” rating reaffirmed by equities research analysts at WBB Securities in a note issued to investors on Tuesday. They presently have a $60.00 target price on the stock, up from their prior target price of $40.00. WBB Securities’ target price points to a potential upside of 22.60% from the company’s current price.
Other analysts have also issued reports about the stock. Piper Jaffray Cos. restated a “sell” rating and issued a $6.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, June 4th. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Wedbush raised their price target on shares of Sarepta Therapeutics to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday. SunTrust Banks Inc. upgraded shares of Sarepta Therapeutics to a “reduce” rating and raised their price target for the stock from $4.00 to $48.00 in a research report on Tuesday. Finally, Cowen and Company upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $47.52.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 14.02% during midday trading on Tuesday, hitting $55.80. 9,554,782 shares of the company’s stock traded hands. The company has a 50 day moving average price of $27.32 and a 200 day moving average price of $21.07. The firm’s market capitalization is $2.67 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $56.18.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/sarepta-therapeutics-srpt-strong-buy-rating-reiterated-at-wbb-securities.html
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the business posted ($0.87) EPS. Equities analysts anticipate that Sarepta Therapeutics will post ($5.16) earnings per share for the current year.
In related news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas boosted its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter worth about $211,000. First Allied Advisory Services Inc. boosted its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares in the last quarter. Finally, National Planning Corp boosted its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.